Accelerated Cost Synergies and Achieved $2.3 Billion Target One Year Ahead of Plan Reported Net Profit Growth of Approximately +750% YOY, Reflecting Gains on Non-core Asset Sales and Lower Acquisition-related Expenses Robust Operating Cash Flow and Divestiture Proceeds Resulting in Free Cash Flow of JPY 1,237.8 Billion, Driving Deleveraging to Net Debt / Adjusted EBITDA of 3.2x FY2021 Anticipated to be an Inflection Year for Wave 1 Pipeline with Five to Six Wave 1 NMEs Submitted and Under Regulatory Review by the FDA with the Potential for Four Approvals
Takeda Pharmaceutical Company Limited (TOKYO:4502) (NYSE:TAK) (“Takeda”) today announced financial results for fiscal year 2020 (period ended March 31, 2021).